Literature DB >> 17956892

Glycaemic control and serum intact parathyroid hormone levels in diabetic patients on haemodialysis therapy.

Reiichi Murakami1, Shuichi Murakami, Rumi Tsushima, Chiyuki Ueda, Kyoko Mikami, Takanori Ebina, Ryuichiro Kumasaka, Norio Nakamura, Ken Okumura.   

Abstract

BACKGROUND: Osteodystrophy is one of the long-term haemodialysis complications, and in diabetic patients, it mainly occurs as an aplastic or low-turnover type due to their low serum intact parathyroid hormone (iPTH) levels. In the present study, we investigated the role of glycaemic control to the serum iPTH levels in diabetic haemodialysis patients.
METHODS: A total of 162 patients who had started haemodialysis at our hospital in the last 10 years were enrolled. Among them, 80 patients suffered from diabetic nephropathy as a primary cause of end-stage renal failure, 69 chronic glomerulonephritis, 9 polycystic kidney and 4 from other causes. We examined the serum iPTH and HbA(1c) levels of all patients at the start of haemodialysis. In 80 diabetic patients, we examined those levels both at the start of haemodialysis and 1 year later and investigated how glycaemic control affected the iPTH levels.
RESULTS: The serum iPTH levels at the start of haemodialysis were significantly lower in patients with diabetes than without diabetes (P=0.032). The levels were lower in patients with poor glycaemic control than with good control (P=0.045). In the analysis of diabetic patients 1 year later, the serum iPTH levels were significantly reduced in those with poor glycaemic control (P=0.002). The multiple regression test showed that the serum HbA(1c) levels were strongly related to the serum iPTH levels (P<0.001).
CONCLUSIONS: The status of glycaemic control in diabetic haemodialysis patients affects the serum iPTH levels. Good glycaemic control should be required to prevent osteodystrophy.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17956892     DOI: 10.1093/ndt/gfm639

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  6 in total

Review 1.  Diseases of the parathyroid gland in chronic kidney disease.

Authors:  Hirotaka Komaba; Takatoshi Kakuta; Masafumi Fukagawa
Journal:  Clin Exp Nephrol       Date:  2011-08-06       Impact factor: 2.801

2.  Serum iPTH, calcium and phosphate, and the risk of mortality in a European haemodialysis population.

Authors:  Jürgen Floege; Joseph Kim; Elizabeth Ireland; Charles Chazot; Tilman Drueke; Angel de Francisco; Florian Kronenberg; Daniele Marcelli; Jutta Passlick-Deetjen; Guntram Schernthaner; Bruno Fouqueray; David C Wheeler
Journal:  Nephrol Dial Transplant       Date:  2010-04-25       Impact factor: 5.992

3.  Vitamin D deficiency--prognostic marker or mortality risk factor in end stage renal disease patients with diabetes mellitus treated with hemodialysis--a prospective multicenter study.

Authors:  Adalbert Schiller; Florica Gadalean; Oana Schiller; Romulus Timar; Flaviu Bob; Mircea Munteanu; Dana Stoian; Adelina Mihaescu; Bogdan Timar
Journal:  PLoS One       Date:  2015-05-12       Impact factor: 3.240

4.  Clinical Characteristics of Patients with Diabetic Nephropathy on Maintenance Hemodialysis: A Multicenter Cross-sectional Survey in Anhui Province, Eastern China.

Authors:  Hu Chen; De-Guang Wang; Liang Yuan; Gui-Ling Liu; Heng-Jie He; Juan Wang; Sen Zhang; Li Hao
Journal:  Chin Med J (Engl)       Date:  2016-06-05       Impact factor: 2.628

5.  Mineral and bone disorder and management in the China Dialysis Outcomes and Practice Patterns Study.

Authors:  Jun Wang; Brian A Bieber; Fan-Fan Hou; Friedrich K Port; Shuchi Anand
Journal:  Chin Med J (Engl)       Date:  2019-12-05       Impact factor: 2.628

6.  Malnutrition-Inflammation Complex Syndrome With Associated Atherosclerosis and Chronic Kidney Disease: A Case Report.

Authors:  Lakshmi Kannan
Journal:  Cureus       Date:  2022-03-29
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.